488 related articles for article (PubMed ID: 25185097)
1. Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
Chawla SP; Cranmer LD; Van Tine BA; Reed DR; Okuno SH; Butrynski JE; Adkins DR; Hendifar AE; Kroll S; Ganjoo KN
J Clin Oncol; 2014 Oct; 32(29):3299-306. PubMed ID: 25185097
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.
Tap WD; Papai Z; Van Tine BA; Attia S; Ganjoo KN; Jones RL; Schuetze S; Reed D; Chawla SP; Riedel RF; Krarup-Hansen A; Toulmonde M; Ray-Coquard I; Hohenberger P; Grignani G; Cranmer LD; Okuno S; Agulnik M; Read W; Ryan CW; Alcindor T; Del Muro XFG; Budd GT; Tawbi H; Pearce T; Kroll S; Reinke DK; Schöffski P
Lancet Oncol; 2017 Aug; 18(8):1089-1103. PubMed ID: 28651927
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
Ganjoo KN; Cranmer LD; Butrynski JE; Rushing D; Adkins D; Okuno SH; Lorente G; Kroll S; Langmuir VK; Chawla SP
Oncology; 2011; 80(1-2):50-6. PubMed ID: 21625179
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.
Borad MJ; Reddy SG; Bahary N; Uronis HE; Sigal D; Cohn AL; Schelman WR; Stephenson J; Chiorean EG; Rosen PJ; Ulrich B; Dragovich T; Del Prete SA; Rarick M; Eng C; Kroll S; Ryan DP
J Clin Oncol; 2015 May; 33(13):1475-81. PubMed ID: 25512461
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of pazopanib plus TH-302 in advanced solid tumors.
Riedel RF; Meadows KL; Lee PH; Morse MA; Uronis HE; Blobe GC; George DJ; Crawford J; Niedzwiecki D; Rushing CN; Arrowood CC; Hurwitz HI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):611-619. PubMed ID: 28238078
[TBL] [Abstract][Full Text] [Related]
6. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.
Ryan CW; Merimsky O; Agulnik M; Blay JY; Schuetze SM; Van Tine BA; Jones RL; Elias AD; Choy E; Alcindor T; Keedy VL; Reed DR; Taub RN; Italiano A; Garcia Del Muro X; Judson IR; Buck JY; Lebel F; Lewis JJ; Maki RG; Schöffski P
J Clin Oncol; 2016 Nov; 34(32):3898-3905. PubMed ID: 27621408
[TBL] [Abstract][Full Text] [Related]
7. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
[TBL] [Abstract][Full Text] [Related]
8. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.
Chawla SP; Papai Z; Mukhametshina G; Sankhala K; Vasylyev L; Fedenko A; Khamly K; Ganjoo K; Nagarkar R; Wieland S; Levitt DJ
JAMA Oncol; 2015 Dec; 1(9):1272-80. PubMed ID: 26378637
[TBL] [Abstract][Full Text] [Related]
9. Tumor hypoxia is a therapeutic target in soft-tissue sarcoma.
Cancer Discov; 2014 Nov; 4(11):OF21. PubMed ID: 25367963
[TBL] [Abstract][Full Text] [Related]
10. A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS).
Lewin J; Malone E; Al-Ezzi E; Fasih S; Pedersen P; Accardi S; Gupta A; Abdul Razak A
Eur J Cancer; 2021 Feb; 144():360-367. PubMed ID: 33418486
[TBL] [Abstract][Full Text] [Related]
11. A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.
Laubach JP; Liu CJ; Raje NS; Yee AJ; Armand P; Schlossman RL; Rosenblatt J; Hedlund J; Martin M; Reynolds C; Shain KH; Zackon I; Stampleman L; Henrick P; Rivotto B; Hornburg KTV; Dumke HJ; Chuma S; Savell A; Handisides DR; Kroll S; Anderson KC; Richardson PG; Ghobrial IM
Clin Cancer Res; 2019 Jan; 25(2):478-486. PubMed ID: 30279233
[TBL] [Abstract][Full Text] [Related]
12. A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.
Chawla SP; Chua VS; Hendifar AF; Quon DV; Soman N; Sankhala KK; Wieland DS; Levitt DJ
Cancer; 2015 Feb; 121(4):570-9. PubMed ID: 25312684
[TBL] [Abstract][Full Text] [Related]
13. The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma.
Constantinidou A; van der Graaf WTA
Eur J Cancer; 2017 Oct; 84():257-261. PubMed ID: 28841543
[TBL] [Abstract][Full Text] [Related]
14. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.
Liu Q; Sun JD; Wang J; Ahluwalia D; Baker AF; Cranmer LD; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1487-98. PubMed ID: 22382881
[TBL] [Abstract][Full Text] [Related]
15. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.
Blay JY; von Mehren M; Samuels BL; Fanucchi MP; Ray-Coquard I; Buckley B; Gilles L; Lebedinsky C; Elsayed YA; Le Cesne A
Clin Cancer Res; 2008 Oct; 14(20):6656-62. PubMed ID: 18927308
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
Chugh R; Griffith KA; Davis EJ; Thomas DG; Zavala JD; Metko G; Brockstein B; Undevia SD; Stadler WM; Schuetze SM
Ann Oncol; 2015 Jul; 26(7):1459-64. PubMed ID: 25858498
[TBL] [Abstract][Full Text] [Related]
18. Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.
Martin-Broto J; Pousa AL; de Las Peñas R; García Del Muro X; Gutierrez A; Martinez-Trufero J; Cruz J; Alvarez R; Cubedo R; Redondo A; Maurel J; Carrasco JA; López-Martin JA; Sala Á; Meana JA; Ramos R; Martinez-Serra J; Lopez-Guerrero JA; Sevilla I; Balaña C; Vaz Á; De Juan A; Alemany R; Poveda A
J Clin Oncol; 2016 Jul; 34(19):2294-302. PubMed ID: 27185843
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study.
Liu Z; Liu C; Yao W; Gao S; Wang J; Zhang P; Ge H
Anticancer Drugs; 2021 Oct; 32(9):962-968. PubMed ID: 34001702
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer HJ; Van Hoesel Q; Blay JY; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J
J Clin Oncol; 2000 Jul; 18(14):2676-84. PubMed ID: 10894866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
